Information date: 26 October 2026 — Imported health foods enter China under the 'Blue Hat' logo through two channels: registration, required for products using ingredients outside the approved nutrient supplement catalogue or claiming new functions, and filing, available for products using listed ingredients with standard function claims. Registration involves technical review with sample testing and typically takes longer than filing, which is a documentary record with post-market obligations. Knowing that statement is not enough for an operating, research or compliance decision. The team must first establish who and what it applies to, how the effect reaches the real process, and which evidence would justify action.
Verified facts and scope
Imported health foods enter China under the 'Blue Hat' logo through two channels: registration, required for products using ingredients outside the approved nutrient supplement catalogue or claiming new functions, and filing, available for products using listed ingredients with standard function claims. Registration involves technical review with sample testing and typically takes longer than filing, which is a documentary record with post-market obligations.
Before choosing a channel, confirm whether every ingredient appears on the approved catalogue for health foods, whether the intended function claim is one of the permitted standard wording, and whether the overseas manufacturing site holds the required certification and has a Chinese responsible agent appointed. Products claiming to treat or prevent disease cannot enter either channel.
How the effect reaches operations
The two channels exist because the regulator trades review depth against ingredient novelty: standard vitamins and minerals with fixed claim wording need only be recorded, while new ingredients or new claims require evidence of safety and function. Function claims are a closed list with prescribed wording, so marketing language that paraphrases or extends a claim beyond the permitted text is a labelling violation rather than a review issue.
The frequent error is filing a product whose formula includes one ingredient outside the catalogue, which forces a late switch to registration and resets the timeline. A second risk is importing and warehousing stock before the Blue Hat approval is issued, since product cannot be sold as health food without it and relabelling as ordinary food is not permitted for products carrying function claims.
For “FAQ: China's 'Blue Hat' Health-Food Route for Imported Supplements — Registration vs Filing, Permitted Function Claims and Review Timelines”, official rules or published findings, direct evidence from the relevant product or process, and assumptions that remain untested should be recorded separately. A broad source defines the external boundary; it does not replace batch records, protocols, contracts, labels or direct observations.
Decision
If the formula uses only catalogue ingredients and a standard claim, pursue filing and plan market entry on the shorter cycle. If any ingredient or claim falls outside the catalogue, budget for registration with sample testing from the start, and avoid committing to retail launch dates until the technical review concludes.
Implementation checklist
- Map every ingredient against the approved health-food ingredient catalogue.
- Select claim wording from the permitted list without paraphrase.
- Appoint a Chinese responsible agent before submitting either application.
- Assign one decision owner, one implementation owner and a dated review point for “FAQ: China's 'Blue Hat' Health-Food Route for Imported Supplements — Registration vs Filing, Permitted Function Claims and Review Timelines”.
- For “FAQ: China's 'Blue Hat' Health-Food Route for Imported Supplements — Registration vs Filing, Permitted Function Claims and Review Timelines”, archive the source page, access date, applicable population or entity, and internal evidence both supporting and opposing the current decision.
- When a rule, formulation, supplier, protocol or observed result changes, reopen only the affected question in “FAQ: China's 'Blue Hat' Health-Food Route for Imported Supplements — Registration vs Filing, Permitted Function Claims and Review Timelines”.
Evidence and review
For “FAQ: China's 'Blue Hat' Health-Food Route for Imported Supplements — Registration vs Filing, Permitted Function Claims and Review Timelines”, start with one real case rather than an abstract checklist. Record the input version, responsible owner, start time, observed result and stop condition. If the team cannot complete “Map every ingredient against the approved health-food ingredient catalogue.” with current evidence, it should not expand the process to more products, patients, suppliers or markets. The first review should focus only on facts capable of changing the decision.
The second control follows “Select claim wording from the permitted list without paraphrase.”. Keep the source date, applicable population or entity, deadline, cost effect and owner in the same evidence file. A wording preference does not justify a new version. A repeated discrepancy, an unsupported health claim or a regulatory mismatch does: correct that point and hold release until the evidence is available.
After “Appoint a Chinese responsible agent before submitting either application.”, compare the intended outcome with what actually happened. Apply the same success criteria to each later expansion. If only one number, date or responsibility changes, update that field and the affected conclusion instead of recreating evidence that remains valid. This keeps the decision traceable without turning review into an open-ended rewrite cycle.
Limits of the conclusion
This FAQ summarises the regulatory pathway and is not food safety, labelling or legal advice; catalogue scope and review timelines are updated by SAMR and should be verified for each formula.
